DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Alimera Sciences

Alimera Sciences

  • NASDAQ Stock Market

    NASDAQ Stock Market

  • Advances in Management of Diabetic Retinopathy Featuring the P

    Advances in Management of Diabetic Retinopathy Featuring the P

  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01

    Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01

  • 05/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 04:25:50 Report Id 2794D052 Page: 01

    05/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 04:25:50 Report Id 2794D052 Page: 01

  • Rebateable Manufacturers

    Rebateable Manufacturers

  • Psivida and Pfizer Amend Agreement to Focus Solely on Development Of

    Psivida and Pfizer Amend Agreement to Focus Solely on Development Of

  • The Bottom 99

    The Bottom 99

  • MANUFACTURERS with CMS AGREEMENTS AS of 5-14-21 Labeler Code Labeler Name Program End Date 00002 ELI LILLY and COMPANY 00003 E.R

    MANUFACTURERS with CMS AGREEMENTS AS of 5-14-21 Labeler Code Labeler Name Program End Date 00002 ELI LILLY and COMPANY 00003 E.R

  • Table of Contents

    Table of Contents

  • Supplier Name

    Supplier Name

  • Psivida Generates up to A$82M from Licensing Amendment with Alimera

    Psivida Generates up to A$82M from Licensing Amendment with Alimera

  • Fueling Life Sciences Through Transformative Transactions

    Fueling Life Sciences Through Transformative Transactions

  • SSSB Minutes 2020 06 FINAL

    SSSB Minutes 2020 06 FINAL

  • 13 Annual Medical Director/ Physician Leadership Forum Expo May 15

    13 Annual Medical Director/ Physician Leadership Forum Expo May 15

  • Psivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN(R) for DME

    Psivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN(R) for DME

  • FULL NAME Contact Company ID Email 3M Company Suzanne Danielson CC0013 Smdanielson@Mmm.Com 3M Unitek Corporation Vincent Martinez CC0361 Vcmartinez@Mmm.Com A-Dec, Inc

    FULL NAME Contact Company ID Email 3M Company Suzanne Danielson CC0013 [email protected] 3M Unitek Corporation Vincent Martinez CC0361 [email protected] A-Dec, Inc

  • Psivida Receives $15 Million Payment from Alimera Sciences

    Psivida Receives $15 Million Payment from Alimera Sciences

  • Show Me Past Attendees to This Event

    Show Me Past Attendees to This Event

Top View
  • 02/10/2015 Provider Subsystem Healthcare and Family Services Run Time: 20:51:09 Report Id 2794D051 Page: 01
  • Medicaid System (Mmis) Illinois Department of Run Date: 02/10/2015 Provider Subsystem Healthcare and Family Services Run Time: 20:51:09 Report Id 2794D052 Page: 01
  • Alimera Sciences Inc
  • Presenter Financial Disclosures for AAO 2020
  • Retina Update: the 10Th Annual J
  • Psivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device in Ocular Hypertension and Glaucoma
  • Active Labelers Run Date : Aug 26, 2021
  • A Comparison of the Efficacy of Brolucizumab and Aflibercept in Eyes with Early Persistent Retinal Fluid: 96–Week Results from the HAWK and HARRIER Studies
  • Taking the Right Measures to Control COVID-19 in Ophthalmology: the Experience of a Tertiary Eye Care Referral Center in Italy
  • THREE PILLARS of SUCCESS in Patient and Practice Management Strategies in Diabetic Macular Edema
  • 4Q2015 Active Labeler Labeler Company 00002 ELI LILLY and COMPANY 00003 E.R
  • Customer Rebate List Covering
  • 2020 Membership Benefits Guide
  • Alimera Sciences. Page 2 of 20 [email protected]
  • The Pharma 1000 Top Global Pharmaceutical Company Report
  • List of Section 13F Securities, Fourth Quarter 2019
  • Alimera Sciences Inc
  • Draft Scope (Post-Referral)


© 2024 Docslib.org    Feedback